Clinical Trial

Alpha-1 Antitrypsin Deficiency Adult Liver Study

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that there is liver injury (inflammation, fibrosis, cirrhosis) in adults with Alpha-1 Antitrypsin Deficiency (AATD), which is asymptomatic, under-recognized, and undiagnosed. In addition, the investigators believe that the genetic and environmental factors that play an important role in the development of alpha-1 antitrypsin (AAT) liver disease, can be identified by comparing a cohort database of clinical disease information to linked biospecimen and DNA samples.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2013-12-17; most recent amendment 2026-04-22.
Status change: Recruiting → Active, Not Recruiting 2023-10-13
Status change: Suspended → Recruiting 2021-03-03
Status change: Recruiting → Suspended 2020-04-23
Trial Details
NCT Number NCT02014415
Lead Sponsor St. Louis University
Collaborators: Alpha-1 Foundation, University of California, Boston University, University College, London, University of Massachusetts, Worcester
Conditions Alpha-1 Antitrypsin Deficiency
Enrollment 120 participants
Start Date 2013-12
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-27